The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires
ongoing monitoring to judge the ability of newly arising variants to escape the immune …

Introduction Pseudoviruses are recombinant, replication-incompetent, viral particles
designed to mimic the surface characteristics of native enveloped viruses. They are a safer …

SARS-CoV-2 variants acquire mutations in spike that promote immune evasion and impact
other properties that contribute to viral fitness such as ACE2 receptor binding and cell entry …

Abstract Avian A (H5N1) influenza virus poses an elevated zoonotic threat to humans, and
no pharmacological products are currently registered for fast-acting pre-exposure protection …

Introduction Convalescent plasma (CP) emerged as potential treatment for COVID-19 early
in the pandemic. While efficacy in hospitalised patients has been lacklustre, CP may be …

Background: The detection of neutralizing anti-SARS-CoV-2 antibodies is important since
they represent the subset of antibodies able to prevent the virus to invade human cells. The …

Lassa virus is estimated to cause thousands of human deaths per year, primarily due to
spillovers from its natural host, Mastomys rodents. Efforts to create vaccines and antibody …

Continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants urges the development of new vaccines. We assessed the safety and …

Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) continues to pose a significant threat to public health globally …

Cases of H5 highly pathogenic avian influenzas (HPAI) are on the rise. Although
mammalian spillover events are rare, H5N1 viruses have an estimated mortality rate in …